1
1 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK Human immunodeficiency virus (HIV) has caused a global pandemic. Associated with premature death from opportunistic infections and malignancies, the uncontrolled virus is devastating. In the UK, an estimated 90 000 people are infected, one third of whom are currently undiagnosed. Since the advent of combination anti-retroviral therapy (cART), the prognosis of HIV has been dramatically transformed and a normal life expectancy is now predicted. However, there is growing recognition that long-term cART is associated with its own complications, particularly metabolic conditions such as hyperlipidaemia and diabetes. Evidence is accumulating that rates of osteoporosis are also increased in these patients. This and other manifestations of so-called premature ageing are increasingly described. The earliest description of the rheumatic manifestations of HIV was published in 1989 and detailed severe seronegative arthritis and psoriasis among patients dying of AIDS. Since then, several studies were published about seronegative arthropathies and HIV. However, much of the literature pre-dates the widespread use of cART. As we will see, HIV may present for the first time with symptoms of an inflammatory rheumatic disease. Moreover, there are syndromes unique to HIV that have similarities to rheumatic diseases and of which rheumatologists should be aware. This lecture will build on the older literature by describing the rheumatic manifestations among a UK cohort of 2000 patients with HIV treated according to modern best practice with cART. As the population with prevalent HIV ages, more patients will develop coexistent inflammatory rheumatic diseases and require disease modifying drugs and biologic therapies on a background of chronic immunosuppression. The literature is sparse at present but the risks/ benefits of standard rheumatological therapies in patients taking cART will be discussed. Disclosure statement: The author has declared no conflicts of interest.
I78. RHEUMATOLOGY IN THE INDIAN SUBCONTINENT: LESSONS RELEVANT TO THE UK
Vinod Ravindran 1 1 Department of Rheumatology, MES Medical College, Perinthalmanna, INDIA It is exciting times for rheumatology in the Indian subcontinent and in India in particular. Though the challenges of inadequate infrastructure, lack of enough trained professionals in rheumatology and its related services in this resource poor country remains, there has been a rapid increase in the knowledge of epidemiology of several rheumatological conditions, more clinical and basic science research in rheumatology is being undertaken and India is not far behind in using advancements in rheumatology health care delivery for its ever increasing population. Due to genetic factors, different clinical expression of certain rheumatological conditions in the Indian subcontinent is being increasingly appreciated. Peculiar infections and certain highly prevalent comorbidities such as diabetes and metabolic syndrome have a bearing not only on the initial clinical picture but also on the subsequent effective management of co-existing rheumatological conditions. Pain and self-reported disability due to chronic rheumatological conditions is also influenced by ethno-cultural factors. Employment and historical reasons are responsible for the large number of people from the Indian subcontinent found in the UK today. Recent 2011 UK census has shown that out of just over 60 million population, over 5% is from the Indian subcontinent. Increase in travel for tourism also has its own health related consequences to the host country. Therefore is likely that colleagues providing rheumatology services in the UK would see an increasing number of patients belonging to the Indian subcontinent. A better understanding of certain aforementioned issues unique to this group would help in optimizing care. However, the use of these outcome measures in the UK is currently limited. Potential targets with regard to disease activity will be discussed. Disclosure statement: R.S. has received honoraria, grants and speaker fees from AbbVie, Pfizer, MSD and UCB.
I81. AN INTERACTIVE TEACHING/DEMONSTRATION OF METROLOGY (BASMI) AND ENTHESITIS (MASES), A REVIEW OF OUTCOME MEASURES (BASDAI, BASFI, AS-WIS etc.), AND EXERCISES FOR ANKYLOSING SPONDYLITIS PATIENTS
Kate Gadsby 1 1 Department of Rheumatology, AbbVie, Maidenhead, UK This is a 90-minute workshop session which is offering a hands-on opportunity to learn and practice skills. The aim of this session is to update delegates on the assessment of disease activity for patients with axial SpA and AS, by the end of the session delegates should: (i) be able to understand the importance of measuring disease activity in the context of modern disease management; (ii) gain practical experience of performing assessments of spinal mobility (BASMI) and assessment of enthesitis (MASES); (iii) understand the different outcome measures used to assess patients; and (iv) gain more familiarity with the exercises recommended for AS patients and increase understanding of how certain exercises increase spinal mobility and flexibility. Disclosure statement: K.G. is a consultant nurse employed by AbbVie.
I82. AN INTERACTIVE TEACHING/DEMONSTRATION OF METROLOGY (BASMI) AND ENTHESITIS (MASES), A REVIEW OF OUTCOME MEASURES (BASDAI, BASFI, AS-WIS, etc.), AND EXERCISES FOR ANKYLOSING SPONDYLITIS PATIENTS

